pharmaphorum
AUGUST 16, 2022
The highly anticipated Lipid Nanoparticle Immunogenicity & Toxicity Summit takes place this December to unite 80+ senior leaders as the definitive meeting for clinical pharmacology , immunogenicity , bioanalytical development leaders to stay at the forefront, arming you with practical takeaways and lessons learned.
European Pharmaceutical Review
MARCH 9, 2023
1 These substances “are pharmacologically and biologically active at low doses,” Dr Kishore Hotha, Global Head of Analytical Research & Development at Veranova, explained. ” Highly potent APIs are pharmacologically and biologically active compounds at low doses. What training is required for employees to handle HPAPIs safely?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
JULY 13, 2023
While this is essential in the interrogation of novel compounds for which we know very little about their efficacy and safety, it is also true that some biomedical research is highly wasteful. An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry.
pharmaphorum
JANUARY 17, 2023
Angion Biomedica ended 2022 in the midst of a strategic review after its lead drug for kidney diseases flamed out, and it has now charted a path forward – a reverse merger with clinical-stage biotech Elicio Therapeutics.
pharmaphorum
DECEMBER 22, 2022
Also tipped as a blockbuster, Zeposia has been gathering momentum with sales doubling to $171 million in the first nine months of 2022. Pfizer reckons the pharmacology of etrasimod – including its engagement with S1P 1, 4 and 5 receptor subtypes – differentiates the drug from its rival, which binds mainly to subtypes 1 and 5.
Legacy MEDSearch
AUGUST 25, 2022
The primary safety endpoint is a performance goal for device and procedure related adverse events at 30 days. The FDA-approved randomized IDE trial has been designed to validate the safety and effectiveness of PiCSO.” Major adverse cardiac events and heart failure endpoints will be captured acutely and for up to 3 years.
European Pharmaceutical Review
MAY 2, 2023
billion in 2022, the average projected return on investment (ROI) in R&D was just 1.2 By collaborating with several stakeholders and authorities, multiple stages of development can take place concurrently to speed up R&D without compromising safety protocols. The COVID-19 blueprint has shown a way forward. Cancer Research UK.
Expert insights. Personalized for you.
52 
Let's personalize your content